Airway Therapeutics will present data on its Ph1b study with zelpultide alfa for prevention for BPD at the 33nd Annual Meeting of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) in Rome this June 2024
Raquel Arroyo, PhD, PharmD, Director, Clinical Sciences, will present data on its Ph1b study with zelpultide alfa for prevention of BPD at the 33nd Annual Meeting of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) in Rome this June 2024.
Airway Therapeutics Featured in Drug Discovery News
Neonatal drug development comes out of the Dark Ages Left out of clinical trials for years, preterm infants have very few drugs developed just for them. Regulators, industry, and neonatologists plan to fix that. Read more: Drug Discovery News July/August 2023 or PDF
Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Favorable safety profile confirmed also in fourth and final cohort including babies born at earliest gestational age of 23 to 24 weeks Interim analysis is complete and full results are expected by October 2023 Company expects to begin a Phase 3 trial by end of 2023 ATLANTA, GEORGIA (June 5, 2023) – Airway Therapeutics, Inc., …
Airway Therapeutics Joins C-Path’s International Neonatal Consortium
TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”) has become a member of its International Neonatal Consortium (INC). Airway is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. Airway is …
Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS
Authors: Ryan R. Manning, Ryan E. Holcomb, Derrick S. Katayama, Giovanni M. Pauletti, Shawn N. Grant, Jan S. Rosenbaum, and Mark Cornell Manning Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS Abstract: Background: Surfactant protein-S (SP-D) is a naturally occurring lung protein with the potential to treat pulmonary infections. A recombinant surfactant protein-D (SP-D) has …
Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Further plans for expansion in Europe include up to ten clinical trial sites across Spain by end of Q32022 and up to three sites in Italy by end of 2022 Zelpultide alfa has been approved as the generic name for our AT-100 (rhSP-D) by the two governing organizations, the United States Adopted Names (USAN) Council …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, GEORGIA (March 31, 2022) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
Novel therapeutic AT-100 offers potential to reduce inflammation, associated injury and incidence of secondary infection, and inhibit viral replication and promote viral elimination in severely ill, mechanically-ventilated COVID-19 patients. Initial data readout anticipated in Q4 2021 CINCINNATI, OH (August 26, 2021) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100’s Second Indication in Severe COVID-19 Patients
Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients CINCINNATI, OH (April 12, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, OH (March 26, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to …